Ultragenyx Pharmaceutical Inc. buy klostergang
Start price
24.01.18
/
50%
€51.42
Target price
01.11.18
€86.41
Performance (%)
-5.41%
End price
01.11.18
€48.64
Summary
This prediction ended on 01.11.18 with a price of €48.64. With a performance of -5.41%, the BUY prediction for Ultragenyx Pharmaceutical Inc. by klostergang closed slightly in the red. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -3.457% | -3.457% | -12.047% | -34.678% |
| iShares Core DAX® | -0,87 % | 5,32 % | 6,86 % | 65,21 % |
| iShares Nasdaq 100 | -0,38 % | 1,98 % | 25,70 % | 90,33 % |
| iShares Nikkei 225® | -1,68 % | 1,95 % | 41,44 % | 80,62 % |
| iShares S&P 500 | -0,65 % | 2,07 % | 21,40 % | 70,74 % |
Comments by klostergang for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
RARE and a PDUFA date in mid-April for burosumab in XLH is a major catalyst.
As for material catalysts to watch for, you look forward to the FDA decision on burosumab with a PDUFA date of April 17th. A decision by the EMA should be forthcoming in the first quarter. Also in the first half of the year we can expect a CHMP opinion for MEPSEVII. In the second half of the year we could potentially see a filing for regulatory approval for UX007 in patients with LC-FAOD should the FDA
accept their early filing. One also expect data from the second cohort of the phase 1/2 study for DTX301 in OTC deficiency around the same time frame.
(Laufzeit überschritten)
Stopped prediction by klostergang for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€52.45
06.07.19
06.07.19
€88.00
04.11.21
04.11.21
54.44%
17.06.21
17.06.21
